Popularity #2,179Earnings today
Rezolute (RZLT)
Developing ersodetug for hypoglycemia caused by congenital and tumor hyperinsulinism.
$4.02
vs last close−0.03 (−0.62%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 90.41% | 87.06M shares | |
|---|---|---|---|
| 152 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 10.70% | 10.30M shares | |
| 10 holders · as of Sep 3, 2026 | |||
| Adds to | 101.11% | ||
96.29M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.11%; nothing is left for Other.
13F, as of Jun 30, 2026
152 holders · 87.06M shares · 41 new positions · 103 increased · 29 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Federated Hermes, Inc. | 12.99M | 13.49% | 0 | Aug 12, 2026 |
| Ra Capital Management, L.P. | 9.45M | 9.81% | +265.0K | Aug 14, 2026 |
| BlackRock, Inc. | 7.72M | 8.02% | +1.40M | Aug 7, 2026 |
| Opaleye Management Inc. | 6.30M | 6.54% | 0 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | 4.66M | 4.84% | −386.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.84M | 3.98% | +313.7K | Aug 13, 2026 |
| Siren, L.L.C. | 3.33M | 3.46% | 0 | Aug 13, 2026 |
| Jacobs Levy Equity Management, Inc | 2.56M | 2.66% | +2.34M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.90% | 9.18M | 13G | Dec 18, 2025 |
| Opaleye Management Inc. | 6.58% | 6.30M | 13G | May 11, 2026 |
| Bank of America Corp /DE/ | 6.50% | 6.06M | 13G | Feb 11, 2026 |
| BlackRock, Inc. | 5.40% | 4.88M | 13G | Oct 17, 2025 |
| Balyasny Asset Management L.P. | 5.28% | 5.05M | 13G | May 15, 2026 |
| Dellora Investments Master Fund LP | 5.10% | 4.87M | 13G | Aug 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 30, 2026 | Daron Evansofficer: CFO | Purchase | 10,000 | $2.85 | 414,462 |
| Dec 16, 2025 | Brian Kenneth Robertsofficer: Chief Medical Officer | Purchase | 28,000 | $1.70 | 308,352 |
| Dec 16, 2025 | Wladimir Hogenhuisdirector | Purchase | 5,650 | $1.69 | 119,675 |
| Dec 15, 2025 | Sunil Ratilal Karnawatofficer: Chief Commercial Officer | Purchase · 2 lots | 12,100 | $1.62 | 71,542 |
| Dec 15, 2025 | Nevan C. Elamdirector, officer: CEO | Purchase | 32,000 | $1.59 | 641,119 |
| Dec 15, 2025 | Daron Evansofficer: CFO | Purchase · 3 lots | 45,000 | $1.77 | 422,900 |
House and Senate disclosures
Not reported.